Atrial Fibrillation (AF) Circulatory System
Conditions
Interventions
Targeted, short-term pharmacological reversal of electrical remodeling is not inferior to prevent recurrent AF after cardioversion when compared to standard long-term antiarrhythmic medication.
Sponsors
German Atrial Fibrillation competence NETwork (AFNET) (Kompetenznetz Vorhofflimmern) (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Documented persistent atrial fibrillation 2. Age of 18 years 3. Documented oral anticoagulation (international normalized ratio [INR] =2) for at least three weeks prior to inclusion, or exclusion of left atrial thrombi by trans-esophageal echocardiography 4. Written informed consent of the patient
Exclusion criteria
Exclusion criteria: Exclusion criteria are based on the approval information of flecainide and include, among others, patients with known coronary artery disease or typical angina pectoris, patients with depressed left ventricular ejection fraction (<40%), patients with severely depressed renal or hepatic function, patients with overt thyroid disease, and patients with known Brugada syndrome, sinus node dysfunction or higher degree AV nodal block.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1. Time to first occurrence of a documented relapse of atrial fibrillation 2. Number of patients with persistent AF after 6 months 3. Number and total duration of documented AF episodes 4. Time to termination of trial medication 5. Number of hospitalizations due to atrial fibrillation 6. Number of visits without hospitalization 7. Number of serious adverse events of special interest 8. Evolution of left ventricular function 9. Quality of life | — |
Primary
| Measure | Time frame |
|---|---|
| Time to first recurrence of persistent AF | — |
Countries
Germany
Outcome results
None listed